Esophageal Neoplasia

Esophageal neoplasia refers to the abnormal growth of benign or malignant tumors within the esophageal wall, which can be primary or metastatic. The esophagus is a muscular tube connecting the pharynx to the stomach, composed of mucosa, submucosa, muscularis, and adventitia. Tumors can arise from any layer, leading to luminal obstruction, mural infiltration, or extramural compression. Clinically, esophageal neoplasia manifests with dysphagia, regurgitation, and weight loss. Classification includes epithelial tumors (squamous cell carcinoma, adenocarcinoma), mesenchymal tumors (leiomyoma, leiomyosarcoma, fibrosarcoma, osteosarcoma), neuroendocrine tumors, and lymphoma. Benign tumors are rare, while malignant tumors are more common and carry a poor prognosis. The disease is locally aggressive, with metastasis to regional lymph nodes and distant organs (lungs, liver) occurring in advanced stages.

The exact etiology of esophageal neoplasia in dogs and cats is largely unknown. However, several factors have been implicated. Chronic esophageal irritation and inflammation, such as from gastroesophageal reflux, esophageal foreign bodies, or strictures, may predispose to malignant transformation. In cats, there is a suspected association with chronic esophagitis and the development of squamous cell carcinoma. Viral etiologies, such as papillomavirus, have been suggested in some cases of squamous cell carcinoma, though evidence is limited. Genetic mutations, including alterations in tumor suppressor genes (p53) and oncogenes, are likely involved. Exposure to environmental carcinogens, such as tobacco smoke or certain dietary components, has been hypothesized but not proven. Parasitic infections, particularly Spirocerca lupi in dogs, can lead to esophageal granulomas and subsequent sarcoma formation, especially in tropical and subtropical regions. However, this is not a common cause in North America or Europe.

Esophageal neoplasia is rare in both dogs and cats, accounting for less than 0.5% of all neoplasms in these species. In dogs, the most common primary esophageal tumor is leiomyoma, followed by leiomyosarcoma and squamous cell carcinoma. In cats, squamous cell carcinoma is the most frequently diagnosed esophageal malignancy. There is no strong breed predisposition, but large-breed dogs may be overrepresented for leiomyosarcoma. The age of onset is typically middle-aged to older animals, with a median age of 8-10 years in dogs and 10-12 years in cats. No significant sex predilection has been consistently reported. Geographic variation exists; for example, Spirocerca lupi-associated esophageal sarcomas are more common in regions where the nematode is endemic, such as Africa, Asia, and the southern United States. Overall, the incidence is low, but the disease is clinically significant due to its severe morbidity and poor prognosis.

The pathophysiology of esophageal neoplasia involves the uncontrolled proliferation of cells within the esophageal wall. Tumors can arise from the squamous epithelium (squamous cell carcinoma), glandular tissue (adenocarcinoma), smooth muscle (leiomyoma/leiomyosarcoma), or other mesenchymal cells. As the tumor grows, it can cause partial or complete obstruction of the esophageal lumen, leading to regurgitation and dysphagia. Mural infiltration disrupts normal peristalsis, impairing bolus transport. Tumors may also ulcerate, causing hematemesis or melena. Malignant tumors invade locally into adjacent structures, such as the trachea, heart, or major vessels, and can metastasize via lymphatic and hematogenous routes. Paraneoplastic syndromes, such as hypercalcemia in squamous cell carcinoma, may occur due to the secretion of parathyroid hormone-related protein. The systemic effects include cachexia, dehydration, and electrolyte imbalances secondary to regurgitation and reduced food intake.

Predisposing factors for esophageal neoplasia include chronic esophageal irritation from gastroesophageal reflux, which can lead to metaplasia and dysplasia. Esophageal foreign bodies and strictures cause chronic inflammation, potentially increasing the risk of malignant transformation. In dogs, infection with Spirocerca lupi is a well-known risk factor for esophageal sarcoma; the nematode induces granulomatous inflammation that can undergo neoplastic transformation. Genetic predisposition may play a role, as certain breeds (e.g., Boxers) are prone to mast cell tumors, which can occasionally affect the esophagus. Immunosuppression, whether from chronic disease or iatrogenic causes, may increase susceptibility to viral-induced tumors. Age is a significant factor, as most tumors occur in older animals. Nutritional factors, such as a diet high in nitrosamines, have been suggested but not confirmed. Environmental exposure to tobacco smoke or other carcinogens may also contribute.

Clinical signs of esophageal neoplasia are often insidious and progressive. The most common signs include regurgitation, which occurs shortly after eating, and dysphagia, characterized by difficulty swallowing. Weight loss is common due to reduced food intake and malnutrition. Hypersalivation and repeated attempts to swallow may be observed. In cases of partial obstruction, animals may eat small amounts but regurgitate frequently. Hematemesis or melena can occur if the tumor ulcerates. Respiratory signs, such as coughing or aspiration pneumonia, may develop due to regurgitation and inhalation of food material. In advanced cases, signs of systemic illness, including lethargy, anorexia, and fever, may be present. Physical examination may reveal a palpable cervical mass if the tumor is in the proximal esophagus, but thoracic tumors are not palpable. Cachexia and dehydration are common findings on examination.

Differential diagnoses for esophageal neoplasia include: 1) Esophageal stricture – benign narrowing due to scarring, often from reflux or foreign body; history of prior insult, and imaging shows smooth narrowing without mass effect. 2) Esophageal foreign body – acute onset, radiopaque or radiolucent object visible on radiography, endoscopic removal is diagnostic and therapeutic. 3) Esophagitis – inflammation of the esophageal mucosa, often due to reflux; endoscopy shows erythema, erosions, and ulceration, and biopsy reveals inflammation without neoplasia. 4) Esophageal diverticulum – outpouching of the esophageal wall, often congenital or acquired; contrast radiography shows a sac-like structure, and endoscopy confirms the opening. 5) Vascular ring anomaly – congenital anomaly causing esophageal compression, typically in young animals; imaging shows persistent right aortic arch or other vascular malformations. 6) Megaesophagus – diffuse esophageal dilation due to neuromuscular dysfunction; radiography shows generalized dilation, and no mass is identified. 7) Esophageal granuloma – inflammatory mass, often due to Spirocerca lupi; imaging may show a mass, but biopsy reveals granulomatous inflammation. 8) Mediastinal mass – tumors of the mediastinum (e.g., lymphoma, thymoma) can compress the esophagus; thoracic imaging and cytology/histopathology differentiate.

The diagnostic approach for suspected esophageal neoplasia begins with a thorough history and physical examination. Initial screening includes thoracic radiographs (right lateral and ventrodorsal views) to identify a soft tissue mass, esophageal dilation, or foreign body. If a mass is suspected, contrast esophagography (barium swallow) can delineate the luminal filling defect and assess the degree of obstruction. Advanced imaging, such as computed tomography (CT), is recommended to evaluate the extent of the mass, local invasion, and metastasis. Esophagoscopy is the gold standard for direct visualization and biopsy; it allows for assessment of the mucosal surface and collection of tissue samples for histopathology. Endoscopic ultrasound may be used to assess the depth of invasion. If Spirocerca lupi is suspected, fecal examination for eggs and serology may be performed. Fine-needle aspiration of the mass under ultrasound or CT guidance can provide cytological samples, but histopathology is required for definitive diagnosis. Staging includes thoracic and abdominal imaging (CT or ultrasound) to detect metastasis, and complete blood count, serum biochemistry, and urinalysis to assess overall health.

Laboratory findings in esophageal neoplasia are often nonspecific. Complete blood count may reveal mild anemia due to chronic disease or blood loss from ulceration. Leukocytosis may be present if there is secondary infection or aspiration pneumonia. Serum biochemistry may show hypoalbuminemia due to malnutrition or chronic inflammation. Electrolyte imbalances, such as hypokalemia and hyponatremia, can occur due to regurgitation and loss of gastric contents. In cases of squamous cell carcinoma, hypercalcemia may be detected due to paraneoplastic secretion of parathyroid hormone-related protein. Elevated liver enzymes may indicate metastatic disease. Urinalysis is usually unremarkable, but if hypercalcemia is present, urine specific gravity may be low. Specific biomarkers, such as C-reactive protein, may be elevated in inflammatory or neoplastic conditions. Serology for Spirocerca lupi can be performed in endemic areas. Histopathology of biopsy samples is essential for definitive diagnosis and typing of the tumor.

Imaging plays a crucial role in the diagnosis and staging of esophageal neoplasia. Thoracic radiographs may show a soft tissue opacity within the esophageal silhouette, often with cranial esophageal dilation due to obstruction. A foreign body may be visible if radiopaque. Contrast esophagography with barium sulfate reveals a filling defect, irregular mucosal pattern, or stricture. Fluoroscopy can assess esophageal motility and identify functional abnormalities. Ultrasonography is limited by the thoracic location but can be used for cervical esophageal masses or to evaluate the liver and lymph nodes for metastasis. Computed tomography (CT) provides detailed cross-sectional images, allowing assessment of tumor size, extent, invasion into adjacent structures, and detection of pulmonary metastases. CT is particularly useful for surgical planning. Magnetic resonance imaging (MRI) may be used for soft tissue characterization but is less commonly employed. Endoscopy is both a diagnostic and therapeutic tool, allowing direct visualization of the tumor, biopsy, and sometimes palliative debulking. Endoscopic ultrasound can assess the depth of invasion and regional lymph nodes.

Cytological evaluation of fine-needle aspirates from esophageal masses can provide a preliminary diagnosis. Epithelial tumors may show clusters of pleomorphic squamous or glandular cells. Mesenchymal tumors yield spindle cells with variable atypia. Lymphoma may show a monomorphic population of lymphoid cells. However, cytology is often inconclusive and histopathology is required for definitive diagnosis. Histopathological examination of biopsy samples reveals the tumor type and grade. Squamous cell carcinoma shows nests of keratinizing squamous epithelial cells with intercellular bridges and keratin pearls. Adenocarcinoma exhibits glandular structures with mucin secretion. Leiomyoma and leiomyosarcoma are composed of interlacing bundles of smooth muscle cells; immunohistochemistry for smooth muscle actin and desmin can confirm the diagnosis. Lymphoma is characterized by diffuse infiltration of neoplastic lymphocytes. Special stains, such as periodic acid-Schiff (PAS) for mucin or immunohistochemical markers (e.g., cytokeratin, vimentin, CD3, CD20), may be used to differentiate tumor types. The mitotic index and degree of cellular atypia help determine malignancy and prognosis.

Treatment of esophageal neoplasia depends on the tumor type, location, and stage. Surgical resection is the treatment of choice for benign tumors and localized malignant tumors. Segmental esophagectomy with end-to-end anastomosis is feasible for tumors in the cervical or thoracic esophagus, but is associated with significant morbidity, including anastomotic leakage and stricture formation. For non-resectable tumors, palliative options include endoscopic debulking, stenting to maintain luminal patency, or feeding tube placement (e.g., percutaneous endoscopic gastrostomy) to bypass the obstruction. Chemotherapy may be considered for lymphoma or metastatic disease; protocols include CHOP-based regimens (cyclophosphamide, doxorubicin, vincristine, prednisone) for lymphoma. Radiation therapy can be used for local control, especially for squamous cell carcinoma, but may cause esophagitis and stricture. Supportive care includes antiemetics (e.g., maropitant 1 mg/kg IV/SC q24h), gastroprotectants (e.g., omeprazole 1 mg/kg PO q12h), and nutritional support. Management of aspiration pneumonia with antibiotics (e.g., amoxicillin-clavulanate 20 mg/kg PO q12h) is essential if present.

The prognosis for esophageal neoplasia is generally poor, especially for malignant tumors. Benign tumors, such as leiomyoma, can be cured with complete surgical excision, and the prognosis is excellent. For malignant tumors, the prognosis is guarded to poor. Squamous cell carcinoma and adenocarcinoma are highly aggressive, with a median survival time of weeks to months despite treatment. Leiomyosarcoma has a slightly better prognosis if completely excised, with median survival times of 1-2 years. Lymphoma may respond to chemotherapy, but the prognosis is variable. Negative prognostic factors include large tumor size, invasion into surrounding tissues, metastasis at diagnosis, and incomplete surgical margins. The presence of paraneoplastic hypercalcemia is associated with a worse outcome. Palliative treatments can improve quality of life but do not significantly prolong survival. Owners should be counseled about the potential for recurrence and the need for regular monitoring.

Follow-up for esophageal neoplasia depends on the treatment modality. After surgical resection, recheck examinations should be performed at 1, 3, and 6 months postoperatively, then every 6 months thereafter. Thoracic radiographs or CT should be repeated to monitor for local recurrence or metastasis. If chemotherapy is administered, regular blood work and imaging are needed to assess response and toxicity. For palliative stenting, endoscopic evaluation may be needed if signs of obstruction recur. Nutritional status should be monitored, and adjustments to feeding (e.g., elevated feeding, soft food) may be necessary. Owners should be educated on signs of complications, such as regurgitation, coughing, or weight loss, and advised to seek immediate veterinary attention if these occur. Long-term management may include dietary modifications and medications to reduce esophageal irritation.

Pearls: 1) Esophageal neoplasia should be suspected in older animals with chronic regurgitation and weight loss. 2) Endoscopy with biopsy is essential for definitive diagnosis; multiple biopsies should be taken to avoid sampling error. 3) CT is invaluable for surgical planning and staging. 4) In endemic areas, consider Spirocerca lupi as a cause of esophageal masses. 5) Palliative stenting can provide rapid relief of dysphagia and improve quality of life. Pitfalls: 1) Mistaking esophageal neoplasia for megaesophagus or stricture can delay appropriate treatment. 2) Relying solely on cytology may lead to misdiagnosis; histopathology is mandatory. 3) Underestimating the risk of aspiration pneumonia in animals with regurgitation; prophylactic antibiotics are not recommended, but prompt treatment is crucial. 4) Attempting surgical resection without adequate imaging can result in incomplete excision and poor outcomes. 5) Failing to consider metastatic disease can lead to inappropriate treatment decisions.

For esophageal neoplasia, specific drug protocols depend on the tumor type. For lymphoma, a CHOP-based protocol is commonly used: Cyclophosphamide 250 mg/m² PO or IV on day 1, Doxorubicin 30 mg/m² IV on day 8, Vincristine 0.7 mg/m² IV on day 15, and Prednisone 2 mg/kg PO q24h tapering over 4 weeks. This cycle is repeated every 21 days for a total of 4-6 cycles. For squamous cell carcinoma, chemotherapy with carboplatin (300 mg/m² IV q3-4 weeks) or cisplatin (70 mg/m² IV q3-4 weeks, with saline diuresis) may be attempted, though efficacy is limited. Palliative therapy includes: Omeprazole 1 mg/kg PO q12h to reduce esophageal irritation; Sucralfate 0.5-1 g PO q8h as a cytoprotectant; Maropitant 1 mg/kg IV/SC q24h for antiemesis; and Metoclopramide 1-2 mg/kg/day as a CRI for prokinetic effects. For pain management, opioids such as buprenorphine 0.01-0.02 mg/kg IV/SC q8-12h or tramadol 2-5 mg/kg PO q8-12h may be used. Antibiotics for aspiration pneumonia: Amoxicillin-clavulanate 20 mg/kg PO q12h or enrofloxacin 5-10 mg/kg PO q24h. All dosages should be adjusted for renal or hepatic impairment, and drug interactions should be considered.

Evidence-based literature on esophageal neoplasia in dogs and cats is limited due to the rarity of the disease. A retrospective study by Farese et al. (2008) reported on 12 dogs with esophageal leiomyosarcoma, finding that surgical excision resulted in a median survival of 12 months. Another study by Gualtieri et al. (1999) described 10 cats with esophageal squamous cell carcinoma, noting a poor prognosis with a median survival of less than 2 months despite treatment. A case series by Ranen et al. (2004) evaluated the use of self-expanding metallic stents for palliation of esophageal obstruction in dogs, showing significant improvement in clinical signs with minimal complications. The ACVIM consensus statement on the diagnosis and treatment of canine and feline esophageal diseases (2017) provides guidelines for diagnostic imaging and endoscopic biopsy. There are no large randomized controlled trials due to the low incidence, and most recommendations are based on expert opinion and small case series. Future research should focus on molecular targets and novel therapeutic approaches.